David J. Woodhouse - 06 Nov 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
Chief Executive Officer, Director
Signature
/s/ Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
06 Nov 2023
Net transactions value
$0
Form type
4
Filing time
08 Nov 2023, 18:09:09 UTC
Previous filing
19 May 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award +255,000 255,000 06 Nov 2023 Common Stock 255,000 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -255,000 -100% 0 06 Nov 2023 Common Stock 255,000 $7.54 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +87,013 87,013 06 Nov 2023 Common Stock 87,013 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -87,013 -100% 0 06 Nov 2023 Common Stock 87,013 $7.70 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +57,833 57,833 06 Nov 2023 Common Stock 57,833 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -57,833 -100% 0 06 Nov 2023 Common Stock 57,833 $8.14 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +500,000 500,000 06 Nov 2023 Common Stock 500,000 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -500,000 -100% 0 06 Nov 2023 Common Stock 500,000 $11.00 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +200,000 200,000 06 Nov 2023 Common Stock 200,000 $0.8400 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -200,000 -100% 0 06 Nov 2023 Common Stock 200,000 $12.06 Direct F1, F2
transaction NGM Stock Option (Right to Buy) Award +400,000 400,000 06 Nov 2023 Common Stock 400,000 $0.8400 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -400,000 -100% 0 06 Nov 2023 Common Stock 400,000 $16.47 Direct F2, F3
transaction NGM Stock Option (Right to Buy) Award +450,000 450,000 06 Nov 2023 Common Stock 450,000 $0.8400 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -450,000 -100% 0 06 Nov 2023 Common Stock 450,000 $31.93 Direct F2, F4
transaction NGM Stock Option (Right to Buy) Award +500,000 500,000 06 Nov 2023 Common Stock 500,000 $0.8400 Direct F2, F5
transaction NGM Stock Option (Right to Buy) Disposed to Issuer -500,000 -100% 0 06 Nov 2023 Common Stock 500,000 $15.20 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
F3 The shares subject to the stock option vest over a four-year period commencing January 1, 2020, with 1/48th of the shares vesting on a monthly basis.
F4 The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
F5 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.